Non-Hodgkin lymphoma (NHL) is a heterogeneous group of cancers. Published recommendations and guidelines for fertility preservation are very general and heterogeneous. Therefore, a very first meta-analysis analyzing the worldwide-published data on the risk of infertility after treatment of NHL is required to better counsel patients regarding fertility issues and to develop further strategies to evaluate the gonadotoxicity of treatments in NHL.
Methods:
A systematic literature search was conducted using Medline, Embase, and Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials (CENTRAL), including articles published since 2000. Exclusion criteria were cases with disease relapse, follow-up of <1 year, testicular NHL, studies with <40% reproductive markers, and case reports. A total of 4602 records were identified. For the systematic review, 58 studies met the inclusion criteria. In this meta-analysis, 51 studies were included.
Results:
The prevalence of expected infertility is 27% (95% confidence interval [CI] 0.20–0.37) overall, 23% (95% CI: 0.14–0.35) in females, and 35% (95% CI: 0.27–0.44) in males. It is highest after chemotherapy and radiotherapy to the pelvis and testis ± bone marrow transplantation, 43% (95% CI: 0.20–0.69) in females and 57% (95% CI: 0.21–0.86) in males. After alkylating agents in females, it is 24% (95% CI: 0.17–0.34).
Conclusion:
The results of this review and meta-analysis indicate a broad heterogeneity of data regarding the risk of infertility. Therefore, fertility counseling and, if necessary, fertility preservation measures are mandatory before oncologic treatment for NHL. Prospective studies stratified by chemotherapy regimen and including new treatment regimens are urgently needed.
Anonymous. RKI Zentrum für Krebsregisterdaten. 2025.
2.
PapeJ, FernandoJ, MegaritisD, et al.Oncological treatments have limited effects on the fertility prognosis in testicular cancer: A systematic review and meta‐analysis. Andrology2025;13(4):731–746; doi: 10.1111/andr.13741
3.
PapeJ, GudzhevaT, DanijelaB, et al.Long-term effects on fertility after central nervous system cancer: A systematic review and meta-analysis. Neuro-Oncol Pract2024;11(6):npae078–n702; doi: 10.1093/nop/npae078
4.
AnthonC, VidalA, ReckerH, et al.Long-Term effects on gonadal function after treatment of colorectal cancer: A systematic review and meta-analysis. Cancers (Basel)2024;16(23):4005; doi: 10.3390/cancers16234005
5.
SteinmannM, RietschinA, PaganoF, et al.Systematic review of the gonadotoxicity and risk of infertility of soft tissue sarcoma chemotherapies in pre- and postpubertal females and males. J Adolesc Young Adult Oncol2024;13(6):803–812; doi: 10.1089/jayao.2024.0057
6.
WeidlingerS, WeidlingerM, SchrammR-M, et al.High impact of chemotherapy on ovarian reserve in breast cancer survivors of reproductive age: A systematic review and meta-analysis. Breast2025;82:104514; doi: 10.1016/j.breast.2025.104514
7.
WeidlingerS, GraberS, BratschiI, et al.A systematic review of the gonadotoxicity of osteosarcoma and ewing’s sarcoma chemotherapies in postpubertal females and males. J Adolesc Young Adult Oncol2024;13(4):597–606; doi: 10.1089/jayao.2023.0185
8.
VidalA, BoraC, JarischA, et al.Impact of haematopoietic stem cell transplantation for benign and malignant haematologic and non-haematologic disorders on fertility: A systematic review and meta-analysis. Bone Marrow Transplant2025;60(5):645–672; doi: 10.1038/s41409-025-02520-6
9.
BujanL, WalschaertsM, BrugnonF, et al.Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: A multicenter prospective study from the CECOS network. Fertil Steril2014;102(3):667–674.e3; doi: 10.1016/j.fertnstert.2014.06.008
10.
BotchanA, HauserR, GamzuR, et al.Sperm quality in Hodgkin’s disease versus non-Hodgkin’s lymphoma. Hum Reprod1997;12(1):73–76; doi: 10.1093/humrep/12.1.73
11.
HallakJ, MahranAM, AgarwalA. Characteristics of cryopreserved semen from men with lymphoma. J Assist Reprod Genet2000;17(10):591–594; doi: 10.1023/A:1026443510493
12.
TalR, BotchanA, HauserR, et al.Follow-up of sperm concentration and motility in patients with lymphoma. Hum Reprod2000;15(9):1985–1988; doi: 10.1093/humrep/15.9.1985
13.
MorganS, AndersonRA, GourleyC, et al.How do chemotherapeutic agents damage the ovary? Hum Reprod Update2012;18(5):525–535; doi: 10.1093/humupd/dms022
14.
ReinmuthS, HohmannC, RendtorffR, et al.Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood: The FeCt—survey of childhood cancer survivors in Germany. J Cancer Res Clin Oncol2013;139(12):2071–2078; doi: 10.1007/s00432-013-1527-9
15.
MüllerU, StahelRA. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol1993;4(5):399–402; doi: 10.1093/oxfordjournals.annonc.a058519
16.
AndersonRA, AmantF, BraatD, ESHRE Guideline Group on Female Fertility Preservation. et al.; ESHRE guideline: Female fertility preservation. Hum Reprod Open2020;2020(4):hoaa052; doi: 10.1093/hropen/hoaa052
17.
Von WolffM, GermeyerA, BöttcherB, et al.Evaluation of the gonadotoxicity of cancer therapies to improve counseling of patients about fertility and fertility preservation measures: Protocol for a retrospective systematic data analysis and a prospective cohort study. JMIR Res Protoc2024;13:e51145; doi: 10.2196/51145
18.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ2021;372:n71; doi: 10.1136/bmj.n71
19.
BorissovN, HaasQ, MinderB, et al.Reducing systematic review burden using Deduklick: A novel, automated, reliable, and explainable deduplication algorithm to foster medical research. Syst Rev2022;11(1):172; doi: 10.1186/s13643-022-02045-9
20.
Van der MierdenS, TsaiounK, BleichA, et al.Software tools for literature screening in systematic reviews in biomedical research. ALTEX2019;36(3):508–517; doi: 10.14573/altex.1902131
21.
BokemeyerC, SchmollHJ, Van RheeJ, et al.Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol1994;68(3):105–110; doi: 10.1007/BF01727413
22.
JacksonGH, WoodA, TaylorPRA, et al.Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Leuk Lymphoma1997;28(1–2):127–132; doi: 10.3109/10428199709058338
23.
BlumenfeldZ, RitterM, Shen-OrrZ, et al.Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity. Am J Reprod Immunol1998;39(1):33–40; doi: 10.1111/j.1600-0897.1998.tb00331.x
24.
HaddyTB, AddeMA, MccallaJ, et al.Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol1998;16(6):2070–2079; doi: 10.1200/JCO.1998.16.6.2070
25.
MertensAC, RamsayNK, KourisS, NegliaJP.Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transplant1998;22(4):345–350; doi: 10.1038/sj.bmt.1701342
26.
Franchi-RezguiP, RousselotP, EspiéM, et al.Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J2003;4(2):116–120.; doi: 10.1038/sj.thj.6200248
27.
DannEJ, EpelbaumR, AviviI, et al.Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod2005;20(8):2247–2249; doi: 10.1093/humrep/dei018
28.
ElisA, TevetA, YerushalmiR, et al.Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma2006;47(4):623–627; doi: 10.1080/10428190500353877
29.
SteffensM, BeauloyeV, BrichardB, et al.Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf)2008;69(5):819–827; doi: 10.1111/j.1365-2265.2008.03283.x
30.
Lie FongS, LavenJSE, Hakvoort-CammelFGAJ, et al.Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod2009;24(4):982–990; doi: 10.1093/humrep/den487
31.
Van WaasM, NeggersSJCMM, Te WinkelML, et al.Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. Ann Oncol2012;23(6):1626–1632; doi: 10.1093/annonc/mdr511
32.
LetourneauJM, EbbelEE, KatzPP, et al.Acute ovarian failure underestimates age‐specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer2012;118(7):1933–1939; doi: 10.1002/cncr.26403
33.
Di PaolaR, CostantiniC, TecchioC, et al.Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies. Oncologist2013;18(12):1307–1314; doi: 10.1634/theoncologist.2013-0138
34.
GreavesP, SarkerS-J, ChowdhuryK, et al.Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol2014;164(4):526–535; doi: 10.1111/bjh.12651
35.
NaessénS, BergströmI, LjungmanP, LandgrenB-M.Long-term follow-up of bone density, general and reproductive health in female survivors after treatment for haematological malignancies. Eur J Haematol2014;93(2):137–142; doi: 10.1111/ejh.12317
36.
AkhtarS, YoussefI, SoudyH, et al.Prevalence of menstrual cycles and outcome of 50 pregnancies after high-dose chemotherapy and auto-SCT in non-Hodgkin and Hodgkin lymphoma patients younger than 40 years. Bone Marrow Transplant2015;50(12):1551–1556; doi: 10.1038/bmt.2015.178
37.
MeissnerJ, TichyD, KatzkeV, et al.Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann Oncol2015;26(8):1771–1776; doi: 10.1093/annonc/mdv227
38.
GuptaAA, Lee ChongA, DeveaultC, et al.Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study. J Pediatr Adolesc Gynecol2016;29(6):599–603; doi: 10.1016/j.jpag.2016.04.009
39.
LasicaM, TaylorE, BhattacharyyaP, et al.Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning. Eur J Haematol2016;97(4):348–352; doi: 10.1111/ejh.12737
40.
GiniG, AnnibaliO, LupascoD, et al.Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma. Chemotherapy2019;64(1):36–41; doi: 10.1159/000499535
41.
Palinska-RudzkaKE, GhobaraT, ParsonsN, et al.Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer. Reprod Biomed Online2019;39(4):712–720; doi: 10.1016/j.rbmo.2019.06.001
42.
LaddagaFE, MoschettaM, PerroneT, et al.Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment. Clin Lymphoma Myeloma Leuk2020;20(8):e506–e512; doi: 10.1016/j.clml.2020.03.006
43.
DecanterC, DelepineJ, BehalH, et al.Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling. Hum Reprod2021;36(10):2743–2752; doi: 10.1093/humrep/deab189
44.
DmitrievaDI, NazarenkoNT, BurduliBA, et al.Fertility outcomes in women after therapy for non-Hodgkin lymphoma. Akusherstvo i Ginekologiia2021;11_2021:187–193; doi: 10.18565/aig.2021.11.187-193
45.
LoAC, ChenB, SamuelV, et al.Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis. J Cancer Surviv2021;15(6):837–846; doi: 10.1007/s11764-020-00976-7
46.
KongkiatkamonS, ChintabanyatA, PolprasertC, et al.Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies. Hematology2022;27(1):181–186; doi: 10.1080/16078454.2022.2026018
47.
BiryukovaBA, AntukhAI, NazarenkoNT, et al.Reproductive function of patients with lymphoproliferative diseases after completion of chemotherapy. Akusherstvo i Ginekologiia2023;7_2023:66–73; doi: 10.18565/aig.2023.79
48.
EntropJP, WeibullCE, SmedbyKE, et al.Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study. Br J Haematol2023;202(4):785–795; doi: 10.1111/bjh.18938
49.
FlattSB, BaillargeonA, McclintockC, et al.Premature ovarian insufficiency in female adolescent and young adult survivors of non-gynecological cancers: a population-based cohort study. Reprod Health2023;20(1); doi: 10.1186/s12978-022-01559-8
50.
PryzantRM, MeistrichML, WilsonG, et al.Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol1993;11(2):239–247; doi: 10.1200/JCO.1993.11.2.239
51.
RadfordJA, ClarkS, CrowtherD, ShaletSM.Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer1994;69(2):379–381; doi: 10.1038/bjc.1994.69
52.
Ben ArushMW, SoltI, LightmanA, et al.Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol2000;17(3):239–245; doi: 10.1080/088800100276415
53.
CicognaniA, CacciariE, PasiniA, et al.Low serum inhibin B levels as a marker of testicular damage after treatment for a childhood malignancy. Eur J Pediatr2000;159(1-2):103–107; doi: 10.1007/s004310050021
54.
KiserudCE, FossåA, BjøroT, et al.Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer2009;100(3):455–463; doi: 10.1038/sj.bjc.6604892
55.
RidolaV, FawazO, AubierF, et al.Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophosphamide-based regimens. European Journal of Cancer2009;45(5):814–818; doi: 10.1016/j.ejca.2009.01.002
56.
Van CasterenNJ, Van Der LindenGHM, Hakvoort-CammelFGAJ, et al.Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer2009;52(1):108–112; doi: 10.1002/pbc.21780
57.
SmitM, Van CasterenNJ, WildhagenMF, et al.Sperm DNA integrity in cancer patients before and after cytotoxic treatment. Hum Reprod2010;25(8):1877–1883; doi: 10.1093/humrep/deq104
58.
HattoriN, GopalAK, ShieldsAT, et al.131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes. Nucl Med Commun2012;33(12):1225–1231; doi: 10.1097/MNM.0b013e328358d34b
59.
Di BisceglieC, BertagnaA, CompostoER, et al.Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders. Asian J Androl2013;15(3):425–429; doi: 10.1038/aja.2012.171
60.
ShiraishiK, MatsuyamaH.Microdissection Testicular Sperm Extraction and Salvage Hormonal Treatment in Patients With Postchemotherapy Azoospermia. Urology2014;83(1):100–106; doi: 10.1016/j.urology.2013.08.043
61.
ServitzoglouM, De VathaireF, OberlinO, et al.Dose-Effect Relationship of Alkylating Agents on Testicular Function in Male Survivors of Childhood Lymphoma. Pediatr Hematol Oncol2015;32(8):613–623; doi: 10.3109/08880018.2015.1085933
62.
MartinezG, WalschaertsM, Le MitouardM, et al.Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: A prospective study by the French CECOS network. Fertil Steril2017;107(2):341–350.e5; doi: 10.1016/j.fertnstert.2016.10.001
63.
GrinsponRP, ArozarenaM, PradaS, et al.Safety of standardised treatments for haematologic malignancies as regards to testicular endocrine function in children and teenagers. Human Reproduction2019;34(12):2480–2494; doi: 10.1093/humrep/dez216
64.
PallottiF, PelloniM, FajaF, et al.Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study. Human Reproduction2021;36(1):16-25; doi: 10.1093/humrep/deaa266
65.
CattoniA, NicolosiML, CapitoliG, et al.Pubertal attainment and Leydig cell function following pediatric hematopoietic stem cell transplantation: a three-decade longitudinal assessment. Front Endocrinol (Lausanne)2023;14:1292683; doi: 10.3389/fendo.2023.1292683
66.
Lopez DacalJ, PradaS, Correa BritoL, et al.Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy. Front Endocrinol (Lausanne)2023;14:1135467; doi: 10.3389/fendo.2023.1135467
67.
WellsG, SheaS, O’ConnellD, et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009.
68.
BrestersD, EmonsJAM, NuriN, et al.Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood. Pediatr Blood Cancer2014;61(11):2048–2053; doi: 10.1002/pbc.25162
69.
PetrekJA, NaughtonMJ, CaseLD, et al.Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol2006;24(7):1045–1051; doi: 10.1200/JCO.2005.03.3969
70.
MeirowD. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol2000;169(1–2):123–131.
71.
GüemesM, Martín-RivadaÁ, Bascuas ArribasM, et al.Endocrine sequelae in 157 pediatric survivors of Hematopoietic Stem Cell Transplantation (HSCT). J Endocr Soc2022;7(2):bvac183; doi: 10.1210/jendso/bvac183
72.
GraciaCR, SammelMD, FreemanE, et al.Impact of cancer therapies on ovarian reserve. Fertil Steril2012;97(1):134–140.e1; doi: 10.1016/j.fertnstert.2011.10.040
73.
AndersonRA, CameronD, ClatotF, et al.Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: A systematic review. Hum Reprod Update2022;28(3):417–434; doi: 10.1093/humupd/dmac004
74.
WnukK, ŚwitalskiJ, MiazgaW, et al.The usage of cryopreserved reproductive material in cancer patients undergoing fertility preservation procedures. Cancers (Basel)2023;15(22):5348; doi: 10.3390/cancers15225348
75.
HawkinsM, DraperG, WinterD. Cancer in the offspring of survivors of childhood leukaemia and non-Hodgkin lymphomas. Br J Cancer1995;71(6):1335–1339; doi: 10.1038/bjc.1995.259
76.
MorrisID. Sperm DNA damage and cancer treatment1. Int J Androl2002;25(5):255–261; doi: 10.1046/j.1365-2605.2002.00372.x
77.
SaloojaN, SzydloRM, SocieG, Late Effects Working Party of the European Group for Blood and Marrow Transplantation. et al.; Pregnancy outcomes after peripheral blood or bone marrow transplantation: A retrospective survey. Lancet2001;358(9278):271–276; doi: 10.1016/S0140-6736%252801%252905482-4
78.
HammerRA, UrnesPD, LurainJR. Unanticipated pregnancy with intrauterine growth retardation after radiation-induced ovarian failure. A case report. J Reprod Med1996;41(5):372–374.
79.
NorwitzER, SternHM, GrierH, Lee-ParritzA. Placenta percreta and uterine rupture associated with prior whole body radiation therapy. Obstet Gynecol2001;98(5 Pt 2):929–931; doi: 10.1016/S0029-7844(01)01435-1
80.
SandersJE, HawleyJ, LevyW, et al.Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood1996;87(7):3045–3052.
81.
CritchleyHOD, WallaceWHB. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr2005;2005(34):64–68; doi: 10.1093/jncimonographs/lgi022
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
